NCT07031570Not yet recruiting
Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Retrospective Evaluation of the Efficacy and Safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) Combined With Hepatic Arterial Infusion Chemotherapy (HAIC) Versus HAIC Alone in Patients With Unresectable Colorectal Cancer Liver Metastases
Source: ClinicalTrials.gov · Last updated 22 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 4 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Colorectal cancer
- NCT number
- NCT07031570
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Jul 2025 to the primary completion date, 30 Sept 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent diagnosis of other malignancies.
- DEB-TACE combined with HAIC or HAIC alone was used as postoperative adjuvant therapy.
Other illness
- Follow-up failure due to incorrect or missing patient information, loss to follow-up, or patient refusal.
- \-
Other
- Presence of treatment risks or contraindications to DEB-TACE combined with HAIC or HAIC alone.
- Underwent other local treatment modalities during the observation period.
- Missing relevant examination results before or after treatment.
- Incomplete imaging data, making response evaluation impossible.
Who the study is looking for
- Age ≥ 18 years
- No gender restriction
- Pathologically or clinically diagnosed with colorectal liver metastases
- Imaging data available within 31 days prior to enrollment, with at least one measurable lesion (according to RECIST criteria)
- Patients received only DEB-TACE combined with HAIC or HAIC alone during the observation period
- Child-Pugh classification A or B
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.